Search hospitals > Illinois > Ottawa

Illinois CancerCare-Ottawa Clinic

Claim this profile
Ottawa, Illinois 61350
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
416 reported clinical trials
22 medical researchers
Photo of Illinois CancerCare-Ottawa Clinic in OttawaPhoto of Illinois CancerCare-Ottawa Clinic in OttawaPhoto of Illinois CancerCare-Ottawa Clinic in Ottawa

Summary

Illinois CancerCare-Ottawa Clinic is a medical facility located in Ottawa, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Illinois CancerCare-Ottawa Clinic is involved with conducting 416 clinical trials across 523 conditions. There are 22 research doctors associated with this hospital, such as Bryan A. Faller, John Hilton, MD, James L. Wade, and Johanne Weberpals, MD.

Area of expertise

1Cancer
Global Leader
Illinois CancerCare-Ottawa Clinic has run 198 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Illinois CancerCare-Ottawa Clinic has run 114 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative

Top PIs

Clinical Trials running at Illinois CancerCare-Ottawa Clinic

Breast Cancer
Prostate Cancer
Lung Cancer
Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Esophageal Adenocarcinoma
Squamous Cell Carcinoma
Image of trial facility.

Shorter HER2-targeted Therapy

for Breast Cancer

The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk of recurrence by nearly half, and death by a third. However, treatment with trastuzumab can result in cardiotoxicity, including heart failure, as well as the significant cost of treatment and the requirement for patients to attend the chemotherapy unit for treatment every 3 weeks for one year. Therefore there has been increasing interest in identifying which patients can safely have less treatment. The investigators therefore propose a real-world, single arm, multicentre trial evaluating 6 months of HER2 targeted therapy, for patients with early-stage, HER2 positive breast cancer, who achieve a pathological complete response (pCR) with upfront systemic chemotherapy and HER2 targeted therapy.
Recruiting3 awards Phase 43 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Illinois CancerCare-Ottawa Clinic?
Illinois CancerCare-Ottawa Clinic is a medical facility located in Ottawa, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Illinois CancerCare-Ottawa Clinic is involved with conducting 416 clinical trials across 523 conditions. There are 22 research doctors associated with this hospital, such as Bryan A. Faller, John Hilton, MD, James L. Wade, and Johanne Weberpals, MD.
Where is Illinois CancerCare-Ottawa Clinic located?
The Illinois CancerCare-Ottawa Clinic is located at 1200 Starfire Drive, Ottawa, IL 61350, conveniently accessible off I-80 for patients in the area.
Who should I call to ask about financial aid or insurance network?
For financial assistance and billing inquiries at Illinois CancerCare-Ottawa Clinic, patients can use the general contact number (217) 383-3311. For more detailed billing questions, the Central Business Office can be reached at (847) 585-7000. It is advisable to contact the clinic directly for specific departmental information.
What insurance does Illinois CancerCare-Ottawa Clinic accept?
The Illinois CancerCare-Ottawa Clinic accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. Additionally, they accept CorVel, Coventry/First Health/Personal Care, Evolutions, Galaxy, Health Dynamics, Healthlink PPO, HFN PPO, Humana (HMO, PPO Choice POS, Choice Care Network), Multiplan, National Provider Network, PHCS, PHCS Savility PPO, PNA, Preferred Plan, Three Rivers Provider Network. It's recommended to contact the clinic directly to confirm if your specific insurance plan is accepted.
What awards or recognition has Illinois CancerCare-Ottawa Clinic received?
Illinois CancerCare-Ottawa Clinic, located in Ottawa, Illinois, is renowned for its dedication to cancer research and quality care. It has earned the Quality Oncology Practice Initiative (QOPI®) Certification, signifying its adherence to the highest national standards for outpatient hematology-oncology practices. Furthermore, the clinic is celebrated by the Alliance for Clinical Trials in Oncology for being among the top enrollers in clinical research, demonstrating its commitment to pioneering new cancer treatments through clinical trials.